Previous studies reporting serological analysis of inflammatory bowel disease and rheumatoid arthritis patients who received infliximab, an anti-TNF drug, suggested that infliximab attenuates the immunogenicity of vaccines in these patients [46, 47]. The gene discussed is TNF; the disease is inflammatory bowel disease.